Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in J Psychiatry Neurosci

Retrieve available abstracts of 25 articles:
HTML format

Single Articles

    May 2022
  1. WANG L, Yin Y, Feng W, Zhou Y, et al
    Childhood trauma and cognitive deficits in patients with schizophrenia: mediation by orbitofrontal cortex H-shaped sulci volume.
    J Psychiatry Neurosci. 2022;47:E209-E217.
    PubMed     Abstract available

  2. TU PC, Chang WC, Chen MH, Hsu JW, et al
    Identifying common and distinct subcortical volumetric abnormalities in 3 major psychiatric disorders: a single-site analysis of 640 participants.
    J Psychiatry Neurosci. 2022;47:E230-E238.
    PubMed     Abstract available

    March 2022
  3. OHI K, Ishibashi M, Torii K, Hashimoto M, et al
    Differences in subcortical brain volumes among patients with schizophrenia and bipolar disorder and healthy controls.
    J Psychiatry Neurosci. 2022;47:E77-E85.
    PubMed     Abstract available

  4. PAN S, Zhou Y, Yan L, Xuan F, et al
    TGF-beta1 is associated with deficits in cognition and cerebral cortical thickness in first-episode schizophrenia.
    J Psychiatry Neurosci. 2022;47:E86-E98.
    PubMed     Abstract available

  5. WANG J, Su P, Yang J, Xu L, et al
    The D2R-DISC1 protein complex and associated proteins are altered in schizophrenia and normalized with antipsychotic treatment.
    J Psychiatry Neurosci. 2022;47:E134-E147.
    PubMed     Abstract available

    January 2022
  6. OCHI R, Plitman E, Patel R, Tarumi R, et al
    Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels.
    J Psychiatry Neurosci. 2022;47:E1-E10.
    PubMed     Abstract available

  7. TOLL A, Blanco-Hinojo L, Berge D, Duran X, et al
    Multidimensional predictors of negative symptoms in antipsychotic-naive first-episode psychosis.
    J Psychiatry Neurosci. 2022;47:E21-E31.
    PubMed     Abstract available

  8. QI Z, Wang J, Gong J, Su T, et al
    Common and specific patterns of functional and structural brain alterations in schizophrenia and bipolar disorder: a multimodal voxel-based meta-analysis.
    J Psychiatry Neurosci. 2022;47:E32-E47.
    PubMed     Abstract available

  9. PALANIYAPPAN L, Venkatasubramanian G
    The Bayesian brain and cooperative communication in schizophrenia.
    J Psychiatry Neurosci. 2022;47:E48-E54.

  10. Correction: The Bayesian brain and cooperative communication in schizophrenia.
    J Psychiatry Neurosci. 2022;47:E55.

    November 2021
  11. CHENG JS, Hu JH, Chang MY, Lin MS, et al
    Hepatitis C-associated late-onset schizophrenia: a nationwide, population-based cohort study.
    J Psychiatry Neurosci. 2021;46:E583-E591.
    PubMed     Abstract available

  12. SABESAN P, Kasianandan A, Palaniyappan L
    Prescribing differently for women with first-episode psychosis.
    J Psychiatry Neurosci. 2021;46:E711.

  13. OVERBEEK G, Gawne TJ, Reid MA, Kraguljac NV, et al
    A multimodal neuroimaging study investigating resting-state connectivity, glutamate and GABA at 7 T in first-episode psychosis.
    J Psychiatry Neurosci. 2021;46:E702-E710.
    PubMed     Abstract available

  14. DI HOU M, Santoro V, Biondi A, Shergill SS, et al
    A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia.
    J Psychiatry Neurosci. 2021;46:E675-E701.
    PubMed     Abstract available

    September 2021
  15. KIM DD, Barr AM, Rafizadeh R, Procyshyn RM, et al
    Population pharmacokinetics and dosing of long-acting injectable antipsychotics.
    J Psychiatry Neurosci. 2021;46:E516-E517.

  16. DUAN J, Wei Y, Womer FY, Zhang X, et al
    Neurobiological substrates of major psychiatry disorders: transdiagnostic associations between white matter abnormalities, neuregulin 1 and clinical manifestation.
    J Psychiatry Neurosci. 2021;46:E506-E515.
    PubMed     Abstract available

    July 2021
  17. ABE C, Petrovic P, Ossler W, Thompson WH, et al
    Genetic risk for bipolar disorder and schizophrenia predicts structure and function of the ventromedial prefrontal cortex.
    J Psychiatry Neurosci. 2021;46:E441-E450.
    PubMed     Abstract available

    April 2021
  18. PAN Y, Dempster K, Jeon P, Theberge J, et al
    Acute conceptual disorganization in untreated first-episode psychosis: a combined magnetic resonance spectroscopy and diffusion imaging study of the cingulum.
    J Psychiatry Neurosci. 2021;46:E337-E346.
    PubMed     Abstract available

    March 2021
  19. GEE S, Taylor D
    COVID-19 infection causes a reduction in neutrophil counts in patients taking clozapine.
    J Psychiatry Neurosci. 2021;46:E232-E237.
    PubMed     Abstract available

    January 2021
  20. GAREL N, Greenway K, Joober R
    The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder.
    J Psychiatry Neurosci. 2021;46:E164-E165.

    November 2020
  21. SABESAN P, Palaniyappan L
    Therapeutic abstention in the treatment of depression in first-episode psychosis.
    J Psychiatry Neurosci. 2020;44:441-442.

    September 2020
  22. FAIVRE N, Roger M, Pereira M, de Gardelle V, et al
    Confidence in visual motion discrimination is preserved in individuals with schizophrenia.
    J Psychiatry Neurosci. 2020;45:200022.
    PubMed     Abstract available

  23. GAREL N, Bloom D, Joober R
    Treating anxious syndromes with pregabalin in patients with psychosis.
    J Psychiatry Neurosci. 2020;45:370.

    May 2020
  24. LI P, Jing RX, Zhao RJ, Shi L, et al
    Association between functional and structural connectivity of the corticostriatal network in people with schizophrenia and unaffected first-degree relatives.
    J Psychiatry Neurosci. 2020;45:190015.
    PubMed     Abstract available

  25. SISKIND D, Honer WG, Clark S, Correll CU, et al
    Consensus statement on the use of clozapine during the COVID-19 pandemic.
    J Psychiatry Neurosci. 2020;45:222-223.

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.